Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab
Abstract This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome–negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2024-11-01
|
| Series: | Blood Cancer Journal |
| Online Access: | https://doi.org/10.1038/s41408-024-01179-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846158805562294272 |
|---|---|
| author | Elias J. Jabbour Hagop M. Kantarjian Nicola Goekbuget Bijal D. Shah Sabina Chiaretti Jae H. Park Anita W. Rijneveld Lia Gore Shaun Fleming Aaron C. Logan Josep M. Ribera Tobias F. Menne Khalid Mezzi Faraz Zaman Kelly Velasco Nicolas Boissel |
| author_facet | Elias J. Jabbour Hagop M. Kantarjian Nicola Goekbuget Bijal D. Shah Sabina Chiaretti Jae H. Park Anita W. Rijneveld Lia Gore Shaun Fleming Aaron C. Logan Josep M. Ribera Tobias F. Menne Khalid Mezzi Faraz Zaman Kelly Velasco Nicolas Boissel |
| author_sort | Elias J. Jabbour |
| collection | DOAJ |
| description | Abstract This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome–negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell–engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile. |
| format | Article |
| id | doaj-art-43030acbfb3043f888db2a0e7df286c9 |
| institution | Kabale University |
| issn | 2044-5385 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Nature Publishing Group |
| record_format | Article |
| series | Blood Cancer Journal |
| spelling | doaj-art-43030acbfb3043f888db2a0e7df286c92024-11-24T12:11:35ZengNature Publishing GroupBlood Cancer Journal2044-53852024-11-0114111610.1038/s41408-024-01179-4Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomabElias J. Jabbour0Hagop M. Kantarjian1Nicola Goekbuget2Bijal D. Shah3Sabina Chiaretti4Jae H. Park5Anita W. Rijneveld6Lia Gore7Shaun Fleming8Aaron C. Logan9Josep M. Ribera10Tobias F. Menne11Khalid Mezzi12Faraz Zaman13Kelly Velasco14Nicolas Boissel15Department of Leukemia, The University of Texas MD Anderson Cancer CenterDepartment of Leukemia, The University of Texas MD Anderson Cancer CenterDepartment of Medicine II, Goethe University, University HospitalDepartment of Malignant Hematology, Moffitt Cancer CenterHematology, Department of Translational and Precision Medicine, Sapienza University of RomeLeukemia Service, Memorial Sloan Kettering Cancer CenterErasmus MC Cancer InstituteChildren’s Hospital Colorado and the University of Colorado School of Medicine, University of Colorado Cancer CenterDepartment of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia, and Australian Centre for Blood Diseases, Monash UniversityHematology, Blood and Marrow Transplant, and Cellular Therapy Program, Division of Hematology/Oncology, University of California San FranciscoICO-Hospital Germans Trias I Pujol. Josep Carreras Research Institute, Universitat Autònoma de BarcelonaThe Newcastle upon Tyne Hospitals and Newcastle UniversityAmgen IncAmgen IncAmgen IncDivision of Hematology, EA3518 Saint-Louis Institute for Research, Saint-Louis HospitalAbstract This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome–negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell–engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens. However, these intense regimens are not tolerated by all, and high-risk patients still have inferior outcomes. Therefore, designing more effective and less toxic strategies remains key to further improving efficacy and safety outcomes. Overall, the treatment landscape is evolving in the frontline, and integration of blinatumomab into different standard frontline regimens may improve overall outcomes with a favorable safety profile.https://doi.org/10.1038/s41408-024-01179-4 |
| spellingShingle | Elias J. Jabbour Hagop M. Kantarjian Nicola Goekbuget Bijal D. Shah Sabina Chiaretti Jae H. Park Anita W. Rijneveld Lia Gore Shaun Fleming Aaron C. Logan Josep M. Ribera Tobias F. Menne Khalid Mezzi Faraz Zaman Kelly Velasco Nicolas Boissel Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab Blood Cancer Journal |
| title | Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab |
| title_full | Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab |
| title_fullStr | Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab |
| title_full_unstemmed | Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab |
| title_short | Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab |
| title_sort | frontline ph negative b cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab |
| url | https://doi.org/10.1038/s41408-024-01179-4 |
| work_keys_str_mv | AT eliasjjabbour frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT hagopmkantarjian frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT nicolagoekbuget frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT bijaldshah frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT sabinachiaretti frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT jaehpark frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT anitawrijneveld frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT liagore frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT shaunfleming frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT aaronclogan frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT josepmribera frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT tobiasfmenne frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT khalidmezzi frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT farazzaman frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT kellyvelasco frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab AT nicolasboissel frontlinephnegativebcellprecursoracutelymphoblasticleukemiatreatmentandtheemergingroleofblinatumomab |